C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 4.8 HKD -0.21% Market Closed
Market Cap: 56.1B HKD
Have any thoughts about
CSPC Pharmaceutical Group Ltd?
Write Note

CSPC Pharmaceutical Group Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSPC Pharmaceutical Group Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Total Liabilities & Equity
ÂĄ47.9B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities & Equity
ÂĄ17B
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
ÂĄ54.4B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSPC Pharmaceutical Group Ltd
Glance View

Market Cap
57.1B HKD
Industry
Pharmaceuticals

CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.

Intrinsic Value
7.28 HKD
Undervaluation 34%
Intrinsic Value
Price
C

See Also

What is CSPC Pharmaceutical Group Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
47.9B CNY

Based on the financial report for Sep 30, 2024, CSPC Pharmaceutical Group Ltd's Total Liabilities & Equity amounts to 47.9B CNY.

What is CSPC Pharmaceutical Group Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
17%

Over the last year, the Total Liabilities & Equity growth was 10%. The average annual Total Liabilities & Equity growth rates for CSPC Pharmaceutical Group Ltd have been 13% over the past three years , 15% over the past five years , and 17% over the past ten years .

Back to Top